{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:26:16Z","timestamp":1790429176044,"version":"4.1.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,6,21]]},"abstract":"<jats:p>In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96\u2009weeks. HIV-1 RNA &lt;40 copies\/mL was achieved in 163\/272 (60%) Randomized Cohort (RC) participants (with 1 or 2 remaining approved fully active antiretrovirals) and 37\/99 (37%) Non-randomized Cohort (NRC) participants (with 0 fully active antiretrovirals).<\/jats:p>","DOI":"10.1128\/aac.01751-21","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T09:00:14Z","timestamp":1651568414000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1200-3706","authenticated-orcid":true,"given":"Margaret","family":"Gartland","sequence":"first","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Huesped, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-7304","authenticated-orcid":true,"given":"Ricardo Sobhie","family":"Diaz","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Paulista School of Medicine, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kozal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases Section, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine and Microbiology, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"University of Paris, Saint-Louis and Lariboisi\u00e8re Hospitals, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mendo Urbina","sequence":"additional","affiliation":[{"name":"Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Wang","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Du","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiven","family":"Chabria","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Brentford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Garside","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Brentford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-2584","authenticated-orcid":true,"given":"Mark","family":"Krystal","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mannino","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Pierce","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ackerman","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Lataillade","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz554"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1710608"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2017.10.011"},{"key":"e_1_3_3_5_2","article-title":"Identifying heavily treatment-experienced patients in a large administrative claims database","author":"Henegar C","year":"2019","unstructured":"Henegar C, Vannappagari V, Viswanathan S, DeKoven M, Clark A, Ackerman P, Llamoso C. 2019. Identifying heavily treatment-experienced patients in a large administrative claims database. Abstr 10th IAS Conference on HIV Science, Abstr MOPEB236.","journal-title":"Abstr 10th IAS Conference on HIV Science, Abstr MOPEB236"},{"key":"e_1_3_3_6_2","article-title":"Prevalence and outcomes for heavily treatment-experienced (HTE) individuals living with HIV in a European cohort. Abstr 10th IAS Conference on HIV Science","author":"Pelchen-Matthews A","year":"2019","unstructured":"Pelchen-Matthews A, Borges AH, Reekie J, Rasmussen LD, Wiese L, Weber J, Pradier C, Degen O, Paredes R, Tau L, Flamholc L, Gottfredsson M, Kowalska J, Jablonowska E, Mozer-Lisewska I, Radoi R, Vasylyev M, Kusnetsova A, Begovac J, Svedhem V, Clark A, Cozzi-Lepri A, for the EuroSIDA. 2019. Prevalence and outcomes for heavily treatment-experienced (HTE) individuals living with HIV in a European cohort. Abstr 10th IAS Conference on HIV Science. Abstr TUPEB222.","journal-title":"Abstr TUPEB222"},{"key":"e_1_3_3_7_2","volume-title":"Guidelines: version 10.1.","author":"European AIDS Clinical Society","year":"2020","unstructured":"European AIDS Clinical Society. 2020. Guidelines: version 10.1. European AIDS Clinical Society, Brussels, Belgium."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3112"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00513-13"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00177-0"},{"key":"e_1_3_3_12_2","volume-title":"Rukobia presecribing information.","author":"ViiV Healthcare","year":"2020","unstructured":"ViiV Healthcare. 2020. Rukobia presecribing information. ViiV Healthcare, Research Triangle Park, NC."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2460"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00426-12"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa474"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003097"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001602"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt412"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31829726f3"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01173-10"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30240-X"},{"key":"e_1_3_3_22_2","article-title":"Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug\u2013resistant HIV-1 (BRIGHTE study)","author":"Lataillade M","year":"2019","unstructured":"Lataillade M, Lalezari J, Aberg J, Molina J-M, Kozal M, Cahn P, Thomason M, Diaz R, Castagna A, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C. 2019. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug\u2013resistant HIV-1 (BRIGHTE study). Abstr 10th IAS Conference on HIV Science, Abstr MOAB0102.","journal-title":"Abstr 10th IAS Conference on HIV Science, Abstr MOAB0102"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02237-10"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/650002"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002851"},{"key":"e_1_3_3_28_2","article-title":"Clinical impact of antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analysis of the phase 3 BRIGHTE study","author":"Ackerman P","year":"2021","unstructured":"Ackerman P, Wilkin P, Pierce A, Chabria S, Wang M, Clark A, Lataillade M. 2021. Clinical impact of antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analysis of the phase 3 BRIGHTE study. Abstr 11th IAS Conference on HIV Science, Abstr PEB155.","journal-title":"Abstr 11th IAS Conference on HIV Science, Abstr PEB155"},{"key":"e_1_3_3_29_2","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna A","year":"2018","unstructured":"Castagna A, Ferrara M, Galli L, Comi L, Sterrantino G, Cenderello G, Zaccarelli M, Foc\u00e1 E, Roncadori A, Lazzarin A, for the PRESTIGIO Study Group. 2018. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. J Antimicrob Chemother 73:177\u2013182.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1232387"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S84850"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2878"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa178"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab257"},{"key":"e_1_3_3_36_2","article-title":"Exploratory analysis of baseline phenotypic and genotypic parameters in relation to antiviral activity for fostemsavir in heavily treatment-experienced (HTE) patients in the phase 3 BRIGHTE study","volume":"14","author":"Gartland M","year":"2021","unstructured":"Gartland M, Karkera Y, George N, Stewart E, Mannino F, Liao Q, Llamoso C, Ackerman P, Krystal M, Garside L. 2021. Exploratory analysis of baseline phenotypic and genotypic parameters in relation to antiviral activity for fostemsavir in heavily treatment-experienced (HTE) patients in the phase 3 BRIGHTE study. Abstr European Meeting on HIV & Hepatitis, Abstr 14.","journal-title":"Abstr European Meeting on HIV & Hepatitis, Abstr"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01751-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01751-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T10:52:11Z","timestamp":1655808731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01751-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,21]]}},"alternative-id":["10.1128\/aac.01751-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01751-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"2021-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01751-21"}}